Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Caliper forms licensing pact with Agilent:

This article was originally published in Clinica

Executive Summary

Agilent Technologies has gained a non-exclusive licence to Caliper Life Sciences' microfluidics patent estate, which Agilent will use to develop clinical diagnostic applications for its 2100 Bioanalyser and 5100 automated lab-on-chip platform. In addition, the companies have entered into a five-year supply agreement, guaranteeing Caliper an exclusive licence to supply planar LabChip products for Agilent's 2100 Bioanalyser and future instrument platforms. Under the terms of the agreement, Agilent will pay Palo Alto-based Caliper an upfront licensing fee, plus royalties on future sales of diagnostic LabChip products covered under the agreement. The companies have not yet disclosed any further details of the two agreements.

You may also be interested in...

India Rare Disease Policy Proposes Crowdfunding But Patients Feel Let Down

Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.

India’s Hilleman Plans ‘Affordable’ Vaccine Against Group B Strep

India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.

More Surufatinib Cheer For Chi-Med As Second NET Trial Stopped Early

Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts